Three-Fraction Stereotactic Body Radiation Therapy for Isolated Liver Recurrence from Colorectal Cancer
Authors:
Open Access
- 1 July 2009
- journal article
- research article
- Published by SAGE Publications in Tumori Journal
- Vol. 95 (4) , 449-454
Abstract
Aims: To determine the feasibility and efficacy of 3-fraction stereotactic body radiation therapy for isolated colorectal cancer liver metastases. Materials and methods: Ten patients with isolated inoperable liver metastasis from colorectal cancer with progression after salvage chemotherapy underwent stereotactic body radiation therapy. Follow-up was 7–49 months (median, 12). Six patients had a solitary lesion and 4 patients had 2 lesions. Internal target volumes of metastatic liver tumors ranged from 3.4 to 271 ml. Stereotactic body radiation therapy doses ranged from 36 to 51 Gy and were administered in three fractions. All patients demonstrated disease progression despite chemotherapy prior to stereotactic body radiation therapy. Results: Three-year overall survival and local control rates were 40% and 60%, respectively. Tumors with an internal target volume <100 ml showed better local control rate than larger tumors. No severe complication was attributed to the therapy. Conclusion: Our study suggests the potential feasibility of stereotactic body radiation therapy for selected patients with colorectal cancer liver metastasis and no treatment option. The study showed that excellent local control was achieved in patients with a total tumor volume of <100 ml but failed to clarify the role of stereotactic body radiation therapy for larger tumors. Further large scale studies are needed to define the indications of such therapy.Keywords
This publication has 19 references indexed in Scilit:
- Phase I Study of Individualized Stereotactic Body Radiotherapy for Hepatocellular Carcinoma and Intrahepatic CholangiocarcinomaJournal of Clinical Oncology, 2008
- Current role of radiofrequency ablation for the treatment of colorectal liver metastasesBritish Journal of Surgery, 2006
- Treatment of hepatic metastases from colorectal cancer: Many doubts, some certaintiesCancer Treatment Reviews, 2006
- Interim analysis of a prospective phase I/II trial of SBRT for liver metastasesActa Oncologica, 2006
- A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastasesInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2005
- Univariate analysis of factors correlated with tumor control probability of three-dimensional conformal hypofractionated high-dose radiotherapy for small pulmonary or hepatic tumorsInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2004
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI: Journal of the National Cancer Institute, 2000
- Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancerThe Lancet, 1998
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European organization for research and treatment of cancer (EORTC)International Journal of Radiation Oncology - Biology - Physics (IJROBP), 1995
- A Prospective Randomized Trial of Regional Versus Systemic Continuous 5-Fluorodeoxyuridine Chemotherapy in the Treatment of Colorectal Liver MetastasesAnnals of Surgery, 1987